Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
SystImmune Inc.
Study ID
NCT06293898
Phase
PHASE1
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BL-M07D1 — DRUG
    Drug: BL-M07D1 The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized. BL-M17D1 will be administered on Day 1 by intravenous infusion every 3 weeks. Other Names: BL-M07D1

Study Details

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Key Dates

Start date
Feb 9, 2024
Status verified
Mar 2026
Primary completion
Dec 15, 2028
Completion
Apr 15, 2029

Study Design

Enrollment
280 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Dose Escalation
    Beginning with Cycle 1, BL-M07D1 will be administered on Day 1 by (IV) infusion every 3 weeks (D1Q3W)
  • Experimental: Experimental: Dose Finding
    Beginning with Cycle 1, BL-M07D1 will be administered on Day 1 by (IV) infusion every 3 weeks (D1Q3W)
  • Experimental: Experimental: Dose Expansion
    Beginning with Cycle 1, BL-M07D1 will be administered on Day 1 by (IV) infusion every 3 weeks (D1Q3W)

Primary Outcome Measure

Summary of safety [ Time Frame: Though study completion, an average of 24 months ]

Central Contacts

Locations (17)

FacilityCityStateZIPSite coordinators
University of Alabama BirminghamBirminghamAlabama35294
Victoria Daiel
205-895-1729
Nusrat Jahan, MD (PRINCIPAL_INVESTIGATOR)
City of HopeDuarteCalifornia91010
Abheshik Tripathi, MD (PRINCIPAL_INVESTIGATOR)
Cedars SinaiLos AngelesCalifornia90211
Shannon Cyhan
301-248-7855
Jin Sun Bitar, MD (PRINCIPAL_INVESTIGATOR)
Scripps HealthSan DiegoCalifornia92121
Jackie Dexter
Wesleigh Edwards, MD (PRINCIPAL_INVESTIGATOR)
University of MiamiMiamiFlorida33136
Gilberto Lopes, MD (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Research institute - Lake Nona FloridaOrlandoFlorida32827
Cesar Perez Batista, MD (PRINCIPAL_INVESTIGATOR)
Georgia Cancer Center at Augusta UniversityAugustaGeorgia30912
Donna Wheatley
Sharad Ghamande, MD (PRINCIPAL_INVESTIGATOR)
University of Chicago MedicineChicagoIllinois60637
Enya Meade
773-702-7871
Gini Fleming, MD (PRINCIPAL_INVESTIGATOR)
University of Illinois Cancer CenterChicagoIllinois60612
Oana Danciu, MD (PRINCIPAL_INVESTIGATOR)
Dana Farber Cancer InstituteBostonMassachusetts02215
Joyce Liu, MD (PRINCIPAL_INVESTIGATOR)
Karmanos Cancer InstitiuteDetroitMichigan48201
Wasif Saif, MD (PRINCIPAL_INVESTIGATOR)
NYU Langone Hospital - Long Island Investigational PharmacyMineolaNew York11501
Ying Lin
516-663-4895
Nancy Chan, MD (PRINCIPAL_INVESTIGATOR)
Laura & Isaac Perlmutter Cancer Center at NYU Langone HealthNew YorkNew York10016
Catia Neves
646-754-4403
Nancy Chan, MD (PRINCIPAL_INVESTIGATOR)
Providence Portland Medical CenterPortlandOregon97213
Anthony Sylvester
Rachel Sanborn, MD (PRINCIPAL_INVESTIGATOR)
Sarah Cannon Research InstituteNashvilleTennessee37203
Scott Miller
(615) 856-0995
Erica Hamilton, MD (PRINCIPAL_INVESTIGATOR)
Oncology ConsultantsHoustonTexas77030
Laura Guerra
7136000913
Julio Peguero, MD (PRINCIPAL_INVESTIGATOR)
Virginia Cancer SpecialistsFairfaxVirginia22031
Alexander Spira, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Related Studies